22 March 2024
22 March 2024
Enspryng did show statistical significance but Chugai Pharmaceuticals said it did not reach the expected level of clinical benefit.
ARS plans to submit a response to the FDA’s CRL by Q2, with neffy’s product launch expected in H2 2024.
The trial aims to determine whether deferiprone can halt disease progression by reducing iron accumulation in the brain.
Innovate UK will oversee the funding while CGT Catapult will coordinate the ATTC Network.
In the trial, the BLB201 vaccine was found to be immunogenic and well-tolerated in children.
The findings from the FLAURA2 trial showed benefits in NSCLC treatment when Tagrisso was combined with chemotherapy.
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
